| Disease | ELEVEN RAMDOMISED CLINICAL TRIALS OF PERMIXON 7 AGAINST PLACEBO AND ONE EACH AGAINST FINASTERIDE, ALFUZOSIN, PRAZOSIN AND EXTRACT OF PYGEUM AND PLACEBO. DATA WERE ALSO AVAILABLE FROM TWO LARGE, OPEN-ALBEL STUDIES. ALL DATA WERE UTILISED IN A
ALL CLINICAL TRIAL DATA PUBLISHED ON PERMIXON. THE ANALYSIS COMPRISES 13 STUDIES AND 2859 MEN: 1961 ON PERMIXON, 278 ON PLACEBO,545 ON FINESTERIDE, 31 ON ALFUZOSIN, 22 ON PRAZOSIN AND 29 ON EXTRACT OF PYGEUM. THERE WAS LITTLE INFORMATION COMMON
TO THE STUDIES. HOWEVER, ELEVEN STUDIES AHD INFORMATION ON PEAK URINARY FLOW AND ALTHOUGH WIDELY DIFFERENT SYMPTOM SCORES WERE USED IN THE TRIALS, EACH HAD INFORMATION ON NOCTURIA. OVER ALL THE TRIALS THE AVERAGE PLACEBO EFFECT IS ASSOOCIATED
WITH AN INCREASE OF 0.94(S.E.0.49) ML/SOC. THE ESTIMATED EFFECT OF PERMIXON IS AN INCREASE OF FURTHER 1.87(055_ML/SEC IN PEAK FLOW(P <0.001). THERE IS A FURGHER REDUCTION ATTRIBUTABLE TO PERMIXON OF 0.55 (0.10) URINATIONS (P<0.001). THIS META
ANALYSIS OF ALL AVAILABLE PUBLISHED TRIALS OF PERMIXON IN THE TREATMENT OF MEN WITH BPH REVEALS A SIGNIFICANT IMPROVEMENT IN PEAK FLOW RATE AND REDUCTION IN NOCTURIA ABOVE PLACEBO.
A COMMERCIAL PRODUCT, PERMIXON, WAS USED. |